Despite the significantly enhanced tumor accumulation and penetration of bLP versus counterpart D-Lipo, bLP were largely internalized by stromal cells and poorly accessed to cancer cells in tumor, which came into a great limit to exerting the therapeutic effects. The gene discussed is DYNLRB1; the disease is cancer.